The report provides a detailed analysis essential for establishing a Frovatriptan Succinate production plant. It encompasses all critical aspects necessary for Frovatriptan Succinate production, including the cost of Frovatriptan Succinate production, Frovatriptan Succinate plant cost, Frovatriptan Succinate production costs, and the overall Frovatriptan Succinate production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Frovatriptan Succinate production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Frovatriptan Succinate is a medication primarily used in the treatment of acute migraine attacks. It works by constricting blood vessels in the brain, helping to alleviate the symptoms of migraines, such as headaches and nausea. It is commonly prescribed as an oral drug to patients experiencing moderate to severe migraine attacks and provides relief from pain, nausea, and sensitivity to light and sound associated with it. In addition to its use in treating migraines, it is also used for use in managing other types of vascular headaches.
It is often used in the treatment of cluster headaches, which are a less common but severe form of headache. It is generally used for its longer duration of action, which allows patients to manage migraine symptoms effectively for up to 24 hours.
The primary factor that drives the market for Frovatriptan Succinate is its effective use in the treatment of acute migraines, which significantly contributes to its demand in the medical sector. Its application as a medication in the treatment of cluster headaches and managing other forms of headache-related disorders further boosts its demand in the pharmaceutical and healthcare industries. The growing prevalence of migraine cases worldwide, along with the increasing focus on effective pain management, also fuels the demand for Frovatriptan Succinate.
Moreover, procurement practices for Frovatriptan Succinate are influenced by factors such as regulatory approvals, the cost of raw materials, and the efficiency of production processes. Advancements in drug delivery technologies, supplier reliability, sustainability practices, adherence to environmental guidelines, and the continuous need for improved patient care also significantly impact industrial Frovatriptan Succinate procurement.
Raw Material for Frovatriptan Succinate Production
According to the Frovatriptan Succinate production plant project report, the major raw materials for Frovatriptan Succinate production include Cyclohexanedione Monoketal- Hydrazine-Chiral Lactam- Succinic Acid.
Production Process of Frovatriptan Succinate
The extensive Frovatriptan Succinate production cost report consists of the following industrial production process:
- Production via Reductive Amination: The production process of Frovatriptan Succinate begins with the conversion of cyclohexanedione monoketal into amine through reductive amination. Then, this amine undergoes Fischer indolization with hydrazine to form indole nitrile. The desired R isomer of the indole nitrile is isolated through a chiral salt formation with chiral lactam, which produces L-pyroglutamic acid salt. Further, the nitrile group in L-pyroglutamic acid salt is hydrolysed to produce carboxamido indole. Finally, the carboxamido indole is converted to Frovatriptan Succinate in situ by reacting it with succinic acid. The complete method is used for the large-scale synthesis of the active pharmaceutical ingredient, Frovatriptan Succinate.
Frovatriptan Succinate is a serotonin (5-HT1) receptor agonist used for the acute treatment of migraines. It belongs to a class of drugs known as triptans and works by narrowing blood vessels around the brain. It exists in the form of a white to off-white crystalline powder and is odourless. The molecular formula of Frovatriptan Succinate is C18H25N3O6, and its molecular mass is 379.4 g/mol. The density of the compound is approximately 1.25 g/cm³.
The compound has a melting point of around 196-198 degree Celsius. It is soluble in water and ethanol. The compound is generally administered in tablet form and works by constricting blood vessels in the brain to relieve migraine symptoms. Common side effects include dizziness, fatigue, and sensations of warmth or tingling. Prolonged use or overuse should be avoided, especially in individuals with cardiovascular conditions. It is recommended to store Frovatriptan Succinate in a cool, dry place, away from light, to preserve its potency.